References

• Berger, R., Huelsman, M., Strecker, K., Bojic, A., Moser, P., Stanek, B., & Pacher, R. (2002). B- type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation, 105(20), 2392-2397.
• Bonow, R. O. (1996). New insights into the cardiac natriuretic peptides. Circulation 1996; 93:1946-50.
• Burke, M. A., Cotts, W. G. (2007). Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev 2007;12:23-36.
• Dao, Q. Krishnaswamy, P., Kazahegra, R., Harrison, A., Amirnovin, R., Lenert, L. et al. (2001). Utility of b-typenaturietic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85
• Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, JJ., Ponikowski, P., Poole-Wilson, P. A. et al. (2008). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388-442
• El Mahmoud, R., Alibay, Y., Brun-Ney, D., Boulard, J. C., Dubourg, O. Puy H, et al. (2006). Type B natriuretic peptide (BNP) versus N-terminal type B natriuretic propeptide in the diagnosis of cardiac failure in the elderly over 75 population. Arch Mal Coeur Vaiss 2006;99:201-7.
• Felker, G. M., Hasselblad, V., Hernandez, A. F., & O'Connor, C. M. (2009). Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. American heart journal, 158(3), 422-430.
• Grewal, J., McKelvie, R., Lonn, E., Tait, P., Carlsson, J., Gianni, M., ... & Persson, H. (2008). BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. European journal of heart failure, 10(3), 252-259.
• Hill, S. A., Balion C. M., Santaguida, P., McQueen, M. J., Ismaila, A. S., Reichert, S. M., et al. (2008). Evidence for the use of B-type natriuretic peptides for screening symptomatic populations and for diagnosis in primary care. Clin Biochem 2008;41:240-9
• Januzzi, J. L., Camargo, C. A., Anwaruddin, S., Baggish, A. L., Chen, A. A., Krauser, D. G, et al. (2005). The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am J Cardiol 2005;95:948-54.
• Kagiyama, N., Kitai, T., Hayashida, A., Yamaguchi, T., Okumura, T., Kida, K., ... & Matsue, Y. (2019).Prognostic value of BNP reduction during hospitalization in patients with acute heart failure. Journal of cardiac failure, 25(9), 712- 721.
• Mant, J., Al-Mohammad, A., Davis, M., Dawda, P., Gilmour, J., Hardman, S., et al. (2010). Chronic heart failure: NICE clinical guidelines for diagnosis and management in primary and secondary care. National Clinical Guideline Centre 2010.
• Mant, J., Cowie, M. R., Doust, J., Roalfe, A., Barton, P., Glasziou, P., et al. (2009). Systemic review and individual patient data analysis of diagnosis of heart failure with modeling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009;13:13
• McCullough, P. A., Nowak, R. M., McCord, J., Hollander, J. E., Herrmann, H. C., Steg, P. G., et al. (2002). B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106:416-22
• Nakagawa, O., Ogawa, Y., Itoh, H., Suga, S., Komatsu, Y., Kishimoto, I., et al. (1995). Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an 'emergency' cardiac hormone against ventricular overload. J ClinInvest 1995;96:1280-7.
• Pfisterer, M., Buser, P., Rickli, H., Gutmann, M., Erne, P., Rickenbacher, P., ... & Time-CHF Investigators. (2009). BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. Jama, 301(4), 383-392.
• O'Donoghue, M., Chen, A., Baggish, A. L., Anwaruddin, S., Krauser, D. G., Tung, R., et al. (2005). The effects of ejection fraction on N- terminal proBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Card Fail 2005;11:S9-14.
• Porapakkham, P., Porapakkham, P. L., Zimmet, H., Billah, B., & Krum, H. (2009). BNP-Guided Heart Failure Therapy: A Meta-analysis of Randomized Control Trials. Heart, Lung and Circulation, 18, S171.
• Schellenberger, U., O'Rear, J., Guzzetta, A., Jue, R. A., Protter, A. A., Pollitt, N. S., et al. (2006). The precursor to B-type natriuretic peptide is an O- linked glycoprotein. Arch Biochem Biophys 2006;451:160-6.
• Sudoh, T., Kangawa, K., Minamino, N., Matsuo, H. (1988). A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
• Uddin, M. H., Rashid, T., & Chowdhury, S. M. (2017). Role of B-type natriuretic peptide (BNP) in heart failure. International Journal on Disability and Human Development, 16(1), 3-9.
• Wright, S. P., Doughty, R. N., Pearl, A., Gamble, G. D., Whalley, G. A., Walsh, H. J., et al. (2003). Plasma amino-terminal probrain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003;42:1793-800.
• Zaphiriou, A., Robb, S., Murray-Thomas, T., Mendez, G., Fox, K., McDonagh, T., et al. (2005). The diagnostic accuracy of plasma BNP and NT proBNP in patients referred from primary care with suspected heart failure: results of the UK Natriuretic Peptide Study. Eur J Heart Fail 2005;7:537-41